Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.22
+0.07006.09%
Post-market: 1.230.0090+0.74%19:59 EDT
Volume:375.30K
Turnover:456.14K
Market Cap:75.33M
PE:-2.01
High:1.24
Open:1.16
Low:1.16
Close:1.15
52wk High:3.19
52wk Low:0.8700
Shares:61.74M
Float Shares:55.30M
Volume Ratio:0.85
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6085
EPS(LYR):-0.7000
ROE:-218.68%
ROA:-92.10%
PB:3.64
PE(LYR):-1.74

Loading ...

Maia Biotech Completes Enrollment for THIO-101 Phase 2 NSCLC Trial of Ateganosine Plus Cemiplimab

Reuters
·
Oct 07

Maia Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Oct 07

MAIA Biotechnology Releases New Investor Presentation and Update

TIPRANKS
·
Oct 06

Diamond Equity releases update note on MAIA Biotechnology

TIPRANKS
·
Oct 01

MAIA Biotechnology files to sell 751,879 shares of common stock for holders

TIPRANKS
·
Sep 26

Maia Biotechnology - Selling Stockholder Offering 751,879 Shares of Maia Biotechnology Common Stock - SEC Filing

THOMSON REUTERS
·
Sep 26

Maia Biotech Wins Spanish, Portuguese Regulatory Clearance to Screen Patients in THIO-104 Lung Cancer Trial

Reuters
·
Sep 23

Maia Biotechnology Expands Pivotal Phase 3 Thio-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

THOMSON REUTERS
·
Sep 23

Maia Biotechnology - Targets 100 Patients Dosed in Thio-104 by Year-End 2026; Interim Analysis in 2027

THOMSON REUTERS
·
Sep 23

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

GlobeNewswire
·
Sep 23

Maia Biotech Says Phase 3 THIO-104 Trial in Third-Line NSCLC Enrolls 65 Patients

Reuters
·
Sep 22

Maia Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 22

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

GlobeNewswire
·
Sep 22

Maia Biotechnology Wins $2.3 Million NIH Grant for Phase 2 NSCLC Trial Expansion

Reuters
·
Sep 16

Maia Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

THOMSON REUTERS
·
Sep 16

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial

GlobeNewswire
·
Sep 16

Maia Biotechnology Board Member Ramiro Guerrero Boosts Stake with USD 252,284 Share Buy

Reuters
·
Sep 15

Maia Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

THOMSON REUTERS
·
Sep 15

Maia Biotechnology - Directors and Officers Hold 21.34% Stake as of Sept 14, 2026

THOMSON REUTERS
·
Sep 15

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

GlobeNewswire
·
Sep 15